Sputnik V has 91.6% efficacy in Russian trials: Lancet study – ET HealthWorld


HYDERABAD: Even as Russian Covid-19 vaccine Sputnik V is eyeing an emergency use authorisation (EUA) rollout in India in March, medical journal Lancet has said the vaccine has shown an efficacy of 91.6% against symptomatic Covid-19 in a two-dose regimen.

The peer-reviewed journal published interim analysis data of Phase III trials of the vaccine involving over 20,000 adults in Russia on Tuesday. It also tweeted that a sub-analysis of over 2,000 participants aged over 60 years suggested the vaccine was similarly effective and well tolerated in the elderly as well.

A top Dr Reddy’s Laboratories official recently said the company hopes to complete the Indian leg of the clinical trials by February end and roll out Sputnik V in EUA mode in March after approval from the Indian drug regulator Drugs Controller General of India.

Follow and connect with us on , Facebook, Linkedin





Source link

vsngroups

Nishant Agrawal introduces VSN Groups that is one of the most popular blogs on Online Shopping & Trending Breaking News and updated information. The #1 thing about this blog is that it’s the most popular blog that covers news, fashion, lifestyle, healthcare, education, digital marketing, and so on where you’ll also discover a ton of shopping & get updates and tips on fashion, lifestyle, better living and so on.

Leave a Reply

Your email address will not be published. Required fields are marked *